Internal Server Error

ActoGeniX - About the company

ActoGeniX is an acquired company based in Ghent (Belgium), founded in 2006. It operates as an Engineering microbes for in situ expression and secretion of novel biotherapeutic proteins and peptides.. ActoGeniX has raised $57.2M in funding. The company has 351 active competitors, including 140 funded and 83 that have exited. Its top competitors include companies like Ginkgo Bioworks, Syngenta and Spark Therapeutics.

Company Details

ActoGeniX is focused on the development and commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals for the targeted treatment of severe diseases. Its proprietary TopAct platform developed enables the molecular engineering of food-grade microbes (lactococcus lactis) to generate biologically-contained ActoBiotics™ for in situ expression and secretion of novel biotherapeutic proteins and peptides including cytokines, enzymes, hormones, and monoclonal antibodies to the oral and gastrointestinal tract. Its clinical stage products include AG013 which delivers a therapeutic peptide for the prevention and attenuation of oral mucositis, and AG014 which secretes anti-TNF-alpha Fab to treat inflammatory bowel disease with localized delivery minimizing systemic exposure. Acobiotics has the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and autoimmune diseases. The company has been acquired by Intrexon Corp. on Feb 2015.
Social
X
Key Metrics
Founded Year
2006
Location
Ghent, Belgium
Stage
Acquired
Total Funding
$57.2M in 4 rounds
Latest Funding Round
Ranked
Employee Count
5 as on Jul 31, 2026
Similar Companies
Exit Details
Acquired by Precigen (Feb 13, 2015)

ActoGeniX's acquisition details

ActoGeniX got acquired by Precigen on Feb 13, 2015 at an acquisition amount of $*****.
Click here to take a look at ActoGeniX's acquisition in detail
Sign up to download ActoGeniX's company profile

ActoGeniX's funding and investors

ActoGeniX has raised a total funding of $57.2M over 4 rounds. Its first funding round was on Feb 06, 2007. Its latest funding round was a Series B round on Apr 18, 2013 for $*****. 6 investors participated in its latest round. ActoGeniX has 10 institutional investors.

Here is the list of recent funding rounds of ActoGeniX:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Apr 18, 2013
8672356
Series B
4079232
6832407
6999097
8376878
Feb 11, 2009
9021037
Series A
5278192
3547504
3578992
Jul 12, 2007
7714175
Grant (prize money)
1962183
2268203
2135120
lockAccess funding benchmarks and valuations. Sign up today!

ActoGeniX's founders and board of directors

Founder? Claim Profile

ActoGeniX's employee count trend

ActoGeniX has 5 employees as of Jul 26. Here is ActoGeniX's employee count trend over the years:
Employee count trend for ActoGeniX
lockUncover ActoGeniX's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

ActoGeniX's Competitors and alternates

Top competitors of ActoGeniX include Ginkgo Bioworks, Syngenta and Spark Therapeutics. Here is the list of Top 10 competitors of ActoGeniX, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Ginkgo Bioworks
Ginkgo Bioworks
2008, Boston (United States), Public
Autonomous labs for biotechnology, empowering scientists to design the living world
$796M
81/100
2nd
Logo for Syngenta
Syngenta
2000, Basel (Switzerland), Acquired
Developer of technologies and sustainable farming practices for farmers
-
75/100
3rd
Logo for Spark Therapeutics
Spark Therapeutics
2013, Philadelphia (United States), Acquired
Developer of gene therapy for rare diseases
$82.8M
73/100
4th
Logo for Twist Bioscience
Twist Bioscience
2013, San Francisco (United States), Public
Developer of a semiconductor-based DNA synthesis platform
$321M
72/100
5th
Logo for Beam Therapeutics
Beam Therapeutics
2017, Cambridge (United States), Public
Developer of gene therapy using CRISPR base editing to treat diseases
$222M
70/100
6th
Logo for Passage Bio
Passage Bio
2017, Philadelphia (United States), Public
Developer of gene therapies for CNS rare diseases
$226M
69/100
7th
Logo for Codexis
Codexis
2002, Redwood City (United States), Public
Developer of high-performance enzymes for drug discovery
$111M
68/100
8th
Logo for AskBio
AskBio
2001, Durham (United States), Acquired
Developer of AAV technologies for treating genetic and complex disorders
$235M
68/100
9th
Logo for CureVac
CureVac
2000, Tubingen (Germany), Acquired
Developer of mRNA-based therapeutics against cancer and infectious diseases
$975M
67/100
10th
Logo for Antheia
Antheia
2013, Palo Alto (United States), Series C
Genetically engineered yeast cells to produce medicinal products
$176M
67/100
152nd
Logo for ActoGeniX
ActoGeniX
2006, Ghent (Belgium), Acquired
Engineering microbes for in situ expression and secretion of novel biotherapeutic proteins and peptides.
$57.2M
37/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on ActoGeniX's competitors? Click here to see the top ones

ActoGeniX's Investments and acquisitions

ActoGeniX has made no investments or acquisitions yet.

News related to ActoGeniX

•
•
Flanders Backs ActoGeniX - PE HubPE Hub•Jul 14, 2007•ActoGeniX, IWT
•
Login | Evaluate Evaluate•ActoGeniX, IWT
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about ActoGeniX

Explore our recently published companies
  • Active in Time - Northampton based, 2011 founded, Public company
  • Ac Nutrition - Winters based, Unfunded company
  • Akitg - Ourense based, 2005 founded, Unfunded company
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford